GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » PS Ratio

NUVB (Nuvation Bio) PS Ratio : 75.38 (As of Mar. 25, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nuvation Bio's share price is $1.96. Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.03. Hence, Nuvation Bio's PS Ratio for today is 75.38.

Good Sign:

Nuvation Bio Inc stock PS Ratio (=65.34) is close to 1-year low of 65.34

The historical rank and industry rank for Nuvation Bio's PS Ratio or its related term are showing as below:

NUVB' s PS Ratio Range Over the Past 10 Years
Min: 71.1   Med: 295   Max: 623.33
Current: 75.34

During the past 5 years, Nuvation Bio's highest PS Ratio was 623.33. The lowest was 71.10. And the median was 295.00.

NUVB's PS Ratio is ranked worse than
83.08% of 993 companies
in the Biotechnology industry
Industry Median: 8.43 vs NUVB: 75.34

Nuvation Bio's Revenue per Sharefor the three months ended in Dec. 2024 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.03.

Back to Basics: PS Ratio


Nuvation Bio PS Ratio Historical Data

The historical data trend for Nuvation Bio's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio PS Ratio Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
PS Ratio
- - - - 91.72

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 486.67 254.44 91.72

Competitive Comparison of Nuvation Bio's PS Ratio

For the Biotechnology subindustry, Nuvation Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuvation Bio's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's PS Ratio distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's PS Ratio falls into.



Nuvation Bio PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Nuvation Bio's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.96/0.026
=75.38

Nuvation Bio's Share Price of today is $1.96.
Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Nuvation Bio  (NYSE:NUVB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Nuvation Bio PS Ratio Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio Business Description

Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Executives
Kim D Blickenstaff director C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Oleg Nodelman director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Venture Opportunity Fund, Lp director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund Qualified, L.p. director 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Kathryn E Falberg director C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dongfang Liu officer: Chief Medical Officer C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 401, NEW YORK NY 10036
Omega Fund V Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund Iv Gp, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp Manager, Ltd. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
David C. Hanley officer: Chief Technical Operations C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Stacy Markel officer: SVP, Human Resources RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080